This inventor holds 1 USPTO granted patent. Top assignee: Mount Sinai Hospital Corporation. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Liu-Ying Luo: Innovator in Ovarian Cancer Detection
Introduction
Liu-Ying Luo is a prominent inventor based in Toronto, Canada, recognized for his significant contribution to the field of medical diagnostics, particularly in the detection of ovarian cancer. His work aims to enhance the accuracy of early cancer detection, ultimately improving patient outcomes.
Latest Patents
Liu-Ying Luo holds a patent for a groundbreaking method for diagnosing, prognosticating, and monitoring ovarian cancer. This innovative patent centers on the detection of the protein hK10 in a subject's sample, such as serum or tumor tissue extract. The method involves utilizing reagents, particularly antibodies that specifically react with hK10, to measure its presence. Additionally, the patent describes advanced imaging methods for tumors associated with hK10, employing agents that bind to hK10 and are labeled for effective imaging of the tumor.
Career Highlights
Liu-Ying Luo is currently affiliated with Mount Sinai Hospital Corporation, where he utilizes his expertise to advance research and clinical applications in cancer detection. His dedication to improving diagnostic methods has positioned him as a respected figure in his field.
Collaborations
Throughout his career, Liu-Ying Luo has collaborated with esteemed professionals, including Eleftherios P. Diamandis. Such partnerships have facilitated the exchange of ideas and fostered innovations in the diagnostic arena, particularly in the accurate detection of ovarian cancer.
Conclusion
In summary, Liu-Ying Luo's innovative work in ovarian cancer detection through his patented methods showcases his commitment to improving healthcare. His collaboration with professionals in the field further enhances the potential for breakthroughs in cancer diagnostics, emphasizing the importance of early detection and monitoring in patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
